2025
Deucravacitinib in Psoriasis Patients with a History of Malignancy: Follow-up after 4 Years of Deucravacitinib Treatment in the POETYK PSO Program
Lebwohl M, Korman N, Gooderham M, Gottlieb A, Foley P, Eyerich K, Romanelli M, Strober B, Morita A, Li L, Daamen C, Vaile J, Badaka R, Alió A, Puig L. Deucravacitinib in Psoriasis Patients with a History of Malignancy: Follow-up after 4 Years of Deucravacitinib Treatment in the POETYK PSO Program. SKIN The Journal Of Cutaneous Medicine 2025, 9: s538. DOI: 10.25251/skin.10.supp.538.Peer-Reviewed Original ResearchHistory of malignancyOccurrence of malignancyPsoriasis patientsFollow-upDuration of follow-upBaseline patient demographicsTyrosine kinase 2 inhibitorLong-term extensionYear prior to enrollmentTreatment discontinuationClinical characteristicsPatient demographicsPatient withdrawalAdverse eventsDeucravacitinibMalignancyPatient populationMalignant eventsPatientsPsoriasisPooled populationNMSCTrialsBaselineTreatment
2024
Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment.
Abdin R, Gharib R, Bunick C, Issa N. Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment. Journal Of Drugs In Dermatology 2024, 23: 694-696. PMID: 39093648, DOI: 10.36849/jdd.8381.Peer-Reviewed Original ResearchConceptsPlaque psoriasisIL-17AIL-17FAnti-IL-17 biologicsSafety of bimekizumabPathogenesis of psoriasisMonoclonal immunoglobulin G1Psoriasis patientsBimekizumabTreatment optionsClinical trialsPsoriasisMedical literatureClearance timeImmunoglobulin G1Rapidity of responseTreatmentPatientsEfficacyClearancePlaqueBrodalumabCytokinesPathogenesisReceptorsMultimorbidity in psoriasis as a risk factor for psoriatic arthritis: a population-based study
Karmacharya P, Chakradhar R, Hulshizer C, Gunderson T, Ogdie A, Davis J, Wright K, Tollefson M, Duarte-García A, Bekele D, Maradit-Kremers H, Crowson C. Multimorbidity in psoriasis as a risk factor for psoriatic arthritis: a population-based study. Rheumatology 2024, 64: 2199-2203. PMID: 38291896, PMCID: PMC11962958, DOI: 10.1093/rheumatology/keae040.Peer-Reviewed Original ResearchDevelopment of PsA.Classification of psoriatic arthritisPsoriasis patientsPsoriatic arthritisDevelopment of multimorbidityRetrospective cohort studyRochester Epidemiology ProjectPopulation-based incidenceClinical Classifications SoftwareManual chart reviewRank sum testCohort of individualsPsoriasis onsetModerate/severe psoriasisChart reviewBaseline morbidityCompare morbidityEpidemiology ProjectMultimorbidityFollow-upCohort studyIncident cohortPsA.PsoriasisRisk factors
2022
Association of sarcoidosis with psoriasis: a cross-sectional study in the All of Us research program
Murphy M, Leasure A, Damsky W, Cohen J. Association of sarcoidosis with psoriasis: a cross-sectional study in the All of Us research program. Archives Of Dermatological Research 2022, 315: 1439-1441. PMID: 36436011, DOI: 10.1007/s00403-022-02488-z.Peer-Reviewed Original ResearchConceptsCross-sectional studyMatched cross-sectional studyAssociation of sarcoidosisCoexistence of sarcoidosisCommon genetic susceptibilitySimilar immunopathogenesisCardiopulmonary symptomsPsoriasis patientsInflammatory skinMultivariable analysisSystemic diseasePsoriasis casesProgram databaseImmune responseSarcoidosisPsoriasisUs Research ProgramPotential associationGenetic susceptibilityDiseaseImmunopathogenesisAssociationSame individualFurther researchTh1Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
Strober B, Bukhalo M, Armstrong A, Pariser D, Kircik L, Parhami S, Montgomery P, Dickerson T. Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes. SKIN The Journal Of Cutaneous Medicine 2022, 6: 458-462. DOI: 10.25251/skin.6.6.2.Peer-Reviewed Original ResearchPhysician prescribing behaviorPatient outcomesPsoriasis patientsPrescribing behaviorClinical utilityExact testMatch StudyChoice of biologicsFisher's exact testPhysician decision makingBiologic selectionBiologic-naïveClinical outcomesLesional skinPsoriasis treatmentDrug classesPatient responsePatient managementWeek 4PatientsPhysician behaviorPhysiciansHealthcare systemBaselineInterim measurementsSwitching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders
Strober B, Armstrong A, Rubant S, Patel M, Wu T, Photowala H, Crowley J. Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. Journal Of Dermatological Treatment 2022, 33: 2991-2996. PMID: 35839335, DOI: 10.1080/09546634.2022.2095328.Peer-Reviewed Original ResearchConceptsPsoriasis Area Severity IndexPASI 75Plaque psoriasis patientsSevere plaque psoriasisSub-optimal respondersPost Hoc AnalysisSignificant safety eventsPASI 50Plaque psoriasisBiologic therapyPASI scorePsoriasis patientsWashout periodIncomplete responsePatientsSafety eventsSeverity IndexPsoriasisDosesSuboptimal resultsSignificant safety riskDLQIAdalimumabPartial success
2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR
Bissonnette R, Gottlieb A, Langley R, Leonardi C, Papp K, Pariser D, Uy J, Lafferty K, Langholff W, Fakharzadeh S, Berlin J, Brouwer E, Greenspan A, Strober B. Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR. Drug Safety 2021, 44: 699-709. PMID: 34075572, PMCID: PMC8184557, DOI: 10.1007/s40264-021-01065-z.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsHazard ratioIncident usersObservational studyCox model regression analysisAdjusted hazard ratioAdverse cardiovascular eventsReal-world registryInternational observational studyLong-term observational studyDisease-based registryRelevant clinical dataMACE riskUstekinumab exposureCardiovascular eventsPatient characteristicsPsoriasis patientsTreatment cohortsMethodological limitationsComparator groupSafety registryClinical dataRegistry dataModel regression analysisConclusionOur resultsCharacteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
Gottlieb A, Merola J, Cirulli J, Williams C, Linowski G, Paris M, Litman H, Guo N, Emeanuru K, McLean R, Cronin A, Strober B. Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. Dermatology And Therapy 2021, 11: 253-263. PMID: 33475970, PMCID: PMC7858993, DOI: 10.1007/s13555-020-00479-4.Peer-Reviewed Original ResearchCorrona Psoriasis RegistryPsoriasis RegistryMost patientsPsoriatic arthritisRegistry enrollmentApremilast patientsPhase 3 clinical studiesReal-world observational studyConcomitant systemic treatmentPrior biologic exposureCharacteristics of patientsTreatment of psoriasisQuality of lifeHigh rateIndex dateObservational registrySevere psoriasisSystemic medicationsAdult patientsBiologic therapyPatient characteristicsSystemic treatmentBiologic exposureModerate diseasePsoriasis patients
2020
The Skin Microbiome of Inverse Psoriasis
Chung J, Strober B, Weinstock G. The Skin Microbiome of Inverse Psoriasis. 2020, 203-215. DOI: 10.1002/9781119593058.ch10.Peer-Reviewed Original ResearchInverse psoriasisNon-lesion sitesSkin microbiomeSkin sitesHealthy skin sitesNon-lesional sitesPlaque psoriasis patientsSubtypes of psoriasisLongitudinal study designPsoriasis patientsIntertriginous sitesUnknown etiologyPsoriasisSkin diseasesStudy designMore subjectsPilot studyFurther studiesPatientsMicrobial differencesLesionsCohortMicrobiomeSubjectsPathogenesis
2019
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council
Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball A, Barker J, Blauvelt A, Members and Councilors I, Bourcier M, Carvalho A, Cohen A, Foley P, Evans C, Gisondi P, Griffiths C, El-Sayed M, Eschevarria C, Finlay A, Kalb R, Leonardi C, Lynde C, Murphy R, Murakami M, Okubo Y, Prens E, Puig L, Seyger M, Skov L, Terui T, Valenzuela F, Ward N, Wu J, Zheng M. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal Of The American Academy Of Dermatology 2019, 82: 117-122. PMID: 31425723, DOI: 10.1016/j.jaad.2019.08.026.Peer-Reviewed Original ResearchConceptsPsoriasis severityInternational Psoriasis CouncilSystemic therapyTopical therapyConsensus statementUndertreatment of psoriasisBody surface areaPast treatment historyPsoriasis involvementPsoriasis patientsClinical studiesTreatment decisionsDelphi consensusEligibility criteriaTreatment historyPatientsSevere categoryTherapySeverity categoriesSeverity definitionsSeverityDichotomous definitionSeverity classificationDelphi approachUndertreatment
2018
Clinical Goals and Barriers to Effective Psoriasis Care
Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, Cohen AD, de la Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, Iversen L, Kleyn CE, Leonardi CL, Lynde CW, Ryan C, Theng CT, Valenzuela F, Vender R, Wu JJ, Young HS, Kimball AB. Clinical Goals and Barriers to Effective Psoriasis Care. Dermatology And Therapy 2018, 9: 5-18. PMID: 30578464, PMCID: PMC6380974, DOI: 10.1007/s13555-018-0279-5.Peer-Reviewed Original ResearchPsoriasis patientsInternational Psoriasis CouncilResource-poor countriesPsoriasis careAutoimmune diseasesOptimal careEarly treatmentTreatment goalsInnovative therapiesTherapeutic efficacyClinical goalsPatientsTreatment barriersModerate formsDisease impactKey opinion leadersCareClinical sciencePsoriasisGreater gainsTherapyGreater understandingDiseasePsoriasis and suicidality: A review of the literature
Liang SE, Cohen JM, Ho RS. Psoriasis and suicidality: A review of the literature. Dermatologic Therapy 2018, 32: e12771. PMID: 30315629, DOI: 10.1111/dth.12771.Peer-Reviewed Original ResearchConceptsSuicidal ideationSystemic inflammatory skin diseaseEvidence-based clinical decisionsInflammatory skin diseasePsoriasis populationBiologic therapyPsoriasis patientsPsychiatric comorbidityPsoriasisSkin diseasesClinical decisionSuicide attemptsAvailable evidenceSuicidalityMultiple studiesPlausible molecular mechanismPresent reviewAvailable literatureMolecular mechanismsIdeationRiskAssociationReviewComorbiditiesPatientsGenetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients
Patrick M, Stuart P, Raja K, Gudjonsson J, Tejasvi T, Yang J, Chandran V, Das S, Callis-Duffin K, Ellinghaus E, Enerbäck C, Esko T, Franke A, Kang H, Krueger G, Lim H, Rahman P, Rosen C, Weidinger S, Weichenthal M, Wen X, Voorhees J, Abecasis G, Gladman D, Nair R, Elder J, Tsoi L. Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nature Communications 2018, 9: 4178. PMID: 30301895, PMCID: PMC6177414, DOI: 10.1038/s41467-018-06672-6.Peer-Reviewed Original ResearchConceptsPsoriasis patientsPredicting PsAGenetic architectureGenetic markersGenetic signaturesComputational pipelineGenetic differencesPsoriatic arthritis developmentChronic musculoskeletal conditionsCutaneous-only psoriasisArea under the receiver operating curveReceiver operating curvePSC patientsPsA riskPsoriasis subtypesPsoriatic patientsArthritis developmentPsoriatic arthritisPsoriasisPatientsConditional inference forestsShrinkage discriminant analysisPSAMusculoskeletal conditionsOperating curvePsychological stress and psoriasis: a systematic review and meta‐analysis
Snast I, Reiter O, Atzmony L, Leshem Y, Hodak E, Mimouni D, Pavlovsky L. Psychological stress and psoriasis: a systematic review and meta‐analysis. British Journal Of Dermatology 2018, 178: e363-e363. DOI: 10.1111/bjd.16620.Peer-Reviewed Original ResearchPsychological stressStressful eventsRecalled stressful eventsLack of robust evidencePsoriasis patientsDiagnosis of stress disordersChronic inflammatory skin diseaseInfluence of psychological stressPatient recallWorsening of psoriasisInflammatory skin diseaseStress disorderPatient's memoryEvaluate disease severityRobust evidencePsoriasis onsetPsoriasis severityPsoriasisPatientsControl groupDisease severitySkin diseases
2017
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. Journal Of The American Academy Of Dermatology 2017, 77: 88-97.e5. PMID: 28495497, DOI: 10.1016/j.jaad.2017.01.037.Peer-Reviewed Original ResearchConceptsChronic HBV infectionBiologic therapyHBV infectionViral reactivationAntiviral prophylaxisCore antibodyHCV infectionHepatitis BSafety of biologic therapiesHistory of viral hepatitisSystematic reviewIsolated core antibodyHBV core antibodyLow-risk patientsRetrospective cohort study designRetrospective cohort studyReactivated HBV infectionCohort study designPsoriasis patientsViral hepatitisEvaluate safetyFollow-upCohort studyPrimary outcomeTreatment durationPsoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab
Elewski B, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober B. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab. Journal Of Dermatological Treatment 2017, 28: 492-499. PMID: 28266243, DOI: 10.1080/09546634.2017.1294727.Peer-Reviewed Original ResearchConceptsQuality of lifeSeverity Index (PASI) 90 responseDLQI 0/1 responsePASI 75Skin clearancePASI 90Psoriasis AreaDermatology Life Quality Index responseGreater health-related qualityPatients' QOLGreater skin clearancePhase 3 studyHealth-related qualityNew biological therapiesRelevant therapeutic goalSevere psoriasisWeek 52Psoriasis patientsBiological therapyWeek 12Therapeutic goalsTrial dataSustained levelsIgA resultsClearance
2013
Community differentiation of the cutaneous microbiota in psoriasis
Alekseyenko A, Perez-Perez G, De Souza A, Strober B, Gao Z, Bihan M, Li K, Methé B, Blaser M. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome 2013, 1: 31. PMID: 24451201, PMCID: PMC4177411, DOI: 10.1186/2049-2618-1-31.Peer-Reviewed Original ResearchCutaneous microbiotaLesion specimensCommon chronic inflammatory diseaseSkin typeChronic inflammatory diseasePsoriasis patientsPsoriatic patientsContralateral skinDifferential microbiotaInflammatory diseasesSkin colonizationHealthy controlsPsoriatic lesionsLesion siteDiagnostic significanceLesion samplesClinical diagnosisPsoriasis samplesPsoriasisSystemic levelsUseful predictorConclusionsOur resultsMicrobiotaPatientsLesions
2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
Strober B, Poulin Y, Kerdel F, Langley R, Gu Y, Gupta S, Okun M, Papp K. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. Journal Of The American Academy Of Dermatology 2011, 64: 671-681. PMID: 21414495, DOI: 10.1016/j.jaad.2010.03.009.Peer-Reviewed Original ResearchConceptsPhysician global assessmentSuboptimal responseSuboptimal therapyWeek 16Global assessmentPhase IIIb trialChronic plaque psoriasisOpen-label designOpen-label studyPrimary end pointPercentage of patientsNB-UVB phototherapySeverity Index scorePsoriasis clinical trialsTreatment of psoriasisDosage taperingIIIb trialPrior therapyPlaque psoriasisPsoriasis AreaPsoriasis flarePsoriasis patientsSafety profilePatient enrollmentClinical trials
2010
The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
Levine D, Strober B. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Seminars In Cutaneous Medicine And Surgery 2010, 29: 28-34. PMID: 20430305, DOI: 10.1016/j.sder.2010.02.003.Peer-Reviewed Original ResearchConceptsSevere psoriasisUS FoodDrug AdministrationTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsInterleukin-12/23 inhibitorsShort-term safetyT-cell modulatorDevelopment of biologicsBiologic therapyPsoriasis patientsPsoriatic patientsClinical trialsTherapeutic monitoringSpecific patientPatientsBiologicsMedicationsPsoriasisLong-term dataAdministrationTreatmentCurrent bodyInhibitorsEvidence
2008
Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab
Marmon S, Strober B. Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab. Journal Of Investigative Dermatology 2008, 128: 2567-2569. PMID: 18927537, DOI: 10.1038/jid.2008.291.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply